Transforming and Simplifying the Treatment of Pulmonary Embolism: “Safe Dose” Thrombolysis Plus New Oral Anticoagulants

Mohsen Sharifi, Z. Vajó, Wilbur Freeman, Curt Bay, Mirali Sharifi, Frederic Schwartz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Administration of systemic thrombolysis in pulmonary embolism (PE) has been limited to severe forms due to the risk of intracerebral hemorrhage (ICH). There is growing evidence from small studies that low-dose systemic thrombolysis has equal efficacy to standard dose, while eliminating the risk of ICH. Little data exists on the combined use of low-dose systemic thrombolysis and new oral anticoagulants (NOAC). We evaluated the clinical and echocardiographic outcome of patients treated with low or “safe dose” thrombolysis (SDT) and NOAC at intermediate term. Methods: We retrospectively identified 159 patients with massive and submassive PE who were treated with SDT and NOAC over a 2-year period by our group. They were followed prospectively for PE-related mortality, recurrent PE, bleeding, change in right/left ventricle (RV/LV) size, pulmonary artery systolic pressure (PASP), and clinical improvement at a mean follow-up of 18 ± 3 months. Results: At 6 months, the RV/LV size was reduced from 1.29 ± 0.28 to 0.89 ± 0.03 (p 

Original languageEnglish
Pages (from-to)369-374
Number of pages6
JournalLung
Volume193
Issue number3
DOIs
Publication statusPublished - Jun 16 2015

Fingerprint

Pulmonary Embolism
Anticoagulants
Cerebral Hemorrhage
Heart Ventricles
Therapeutics
Pulmonary Artery
Hemorrhage
Blood Pressure
Mortality

Keywords

  • New oral anticoagulants
  • Pulmonary embolism
  • Pulmonary hypertension
  • Safe dose thrombolysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Transforming and Simplifying the Treatment of Pulmonary Embolism : “Safe Dose” Thrombolysis Plus New Oral Anticoagulants. / Sharifi, Mohsen; Vajó, Z.; Freeman, Wilbur; Bay, Curt; Sharifi, Mirali; Schwartz, Frederic.

In: Lung, Vol. 193, No. 3, 16.06.2015, p. 369-374.

Research output: Contribution to journalArticle

Sharifi, Mohsen ; Vajó, Z. ; Freeman, Wilbur ; Bay, Curt ; Sharifi, Mirali ; Schwartz, Frederic. / Transforming and Simplifying the Treatment of Pulmonary Embolism : “Safe Dose” Thrombolysis Plus New Oral Anticoagulants. In: Lung. 2015 ; Vol. 193, No. 3. pp. 369-374.
@article{8f8ab4b3ff644a9d8dfe66f85f3f168a,
title = "Transforming and Simplifying the Treatment of Pulmonary Embolism: “Safe Dose” Thrombolysis Plus New Oral Anticoagulants",
abstract = "Background: Administration of systemic thrombolysis in pulmonary embolism (PE) has been limited to severe forms due to the risk of intracerebral hemorrhage (ICH). There is growing evidence from small studies that low-dose systemic thrombolysis has equal efficacy to standard dose, while eliminating the risk of ICH. Little data exists on the combined use of low-dose systemic thrombolysis and new oral anticoagulants (NOAC). We evaluated the clinical and echocardiographic outcome of patients treated with low or “safe dose” thrombolysis (SDT) and NOAC at intermediate term. Methods: We retrospectively identified 159 patients with massive and submassive PE who were treated with SDT and NOAC over a 2-year period by our group. They were followed prospectively for PE-related mortality, recurrent PE, bleeding, change in right/left ventricle (RV/LV) size, pulmonary artery systolic pressure (PASP), and clinical improvement at a mean follow-up of 18 ± 3 months. Results: At 6 months, the RV/LV size was reduced from 1.29 ± 0.28 to 0.89 ± 0.03 (p ",
keywords = "New oral anticoagulants, Pulmonary embolism, Pulmonary hypertension, Safe dose thrombolysis",
author = "Mohsen Sharifi and Z. Vaj{\'o} and Wilbur Freeman and Curt Bay and Mirali Sharifi and Frederic Schwartz",
year = "2015",
month = "6",
day = "16",
doi = "10.1007/s00408-015-9702-1",
language = "English",
volume = "193",
pages = "369--374",
journal = "Lung",
issn = "0341-2040",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Transforming and Simplifying the Treatment of Pulmonary Embolism

T2 - “Safe Dose” Thrombolysis Plus New Oral Anticoagulants

AU - Sharifi, Mohsen

AU - Vajó, Z.

AU - Freeman, Wilbur

AU - Bay, Curt

AU - Sharifi, Mirali

AU - Schwartz, Frederic

PY - 2015/6/16

Y1 - 2015/6/16

N2 - Background: Administration of systemic thrombolysis in pulmonary embolism (PE) has been limited to severe forms due to the risk of intracerebral hemorrhage (ICH). There is growing evidence from small studies that low-dose systemic thrombolysis has equal efficacy to standard dose, while eliminating the risk of ICH. Little data exists on the combined use of low-dose systemic thrombolysis and new oral anticoagulants (NOAC). We evaluated the clinical and echocardiographic outcome of patients treated with low or “safe dose” thrombolysis (SDT) and NOAC at intermediate term. Methods: We retrospectively identified 159 patients with massive and submassive PE who were treated with SDT and NOAC over a 2-year period by our group. They were followed prospectively for PE-related mortality, recurrent PE, bleeding, change in right/left ventricle (RV/LV) size, pulmonary artery systolic pressure (PASP), and clinical improvement at a mean follow-up of 18 ± 3 months. Results: At 6 months, the RV/LV size was reduced from 1.29 ± 0.28 to 0.89 ± 0.03 (p 

AB - Background: Administration of systemic thrombolysis in pulmonary embolism (PE) has been limited to severe forms due to the risk of intracerebral hemorrhage (ICH). There is growing evidence from small studies that low-dose systemic thrombolysis has equal efficacy to standard dose, while eliminating the risk of ICH. Little data exists on the combined use of low-dose systemic thrombolysis and new oral anticoagulants (NOAC). We evaluated the clinical and echocardiographic outcome of patients treated with low or “safe dose” thrombolysis (SDT) and NOAC at intermediate term. Methods: We retrospectively identified 159 patients with massive and submassive PE who were treated with SDT and NOAC over a 2-year period by our group. They were followed prospectively for PE-related mortality, recurrent PE, bleeding, change in right/left ventricle (RV/LV) size, pulmonary artery systolic pressure (PASP), and clinical improvement at a mean follow-up of 18 ± 3 months. Results: At 6 months, the RV/LV size was reduced from 1.29 ± 0.28 to 0.89 ± 0.03 (p 

KW - New oral anticoagulants

KW - Pulmonary embolism

KW - Pulmonary hypertension

KW - Safe dose thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=84929154881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929154881&partnerID=8YFLogxK

U2 - 10.1007/s00408-015-9702-1

DO - 10.1007/s00408-015-9702-1

M3 - Article

C2 - 25749665

AN - SCOPUS:84929154881

VL - 193

SP - 369

EP - 374

JO - Lung

JF - Lung

SN - 0341-2040

IS - 3

ER -